IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD?
https://doi.org/10.21292/2078-5658-2018-15-3-56-61
Abstract
Despite significant achievements in the management of patients with cardiac vascular pathology, this type of disorders remains to be the major cause of death all over the world. Patients undergoing surgery and suffering from cardiac vascular diseases face a high risk to develop post-operative complications and lethal outcome and about half of the post-operative lethal cases after non-cardiac surgery are caused by cardiac vascular complications. Inhibitors of angiotensin-converting enzyme as well as angiotensin II receptor blockers are the ones of the most frequently used drugs in cardiology; they have been proved to slow down the progress of the disease, improve life quality and reduce mortality. However, the use of these drugs in pre-operative period can be associated with such adverse events as hypotension and post-operative renal dysfunction. Thus, it is necessary to justify therapy with blockers of renin-angiotensin-aldosterone system in the peri-operative period in the patients undergoing cardiac and non-cardiac surgery.
About the Authors
V. V. Lomivorotov
E.N. Meshalkin Research Institute of Blood Circulation Pathology
Russian Federation
Russian Federation
Vladimir V. Lomivorotov - Doctor of Medical Sciences, Professor, Correspindent Member of RAS, Deputy Director for Research, Head of Anesthesiology and Intensive Care Center.
15, Rechkunovskaya St., Novosibirsk, 630055,Phone/Fax: 8 (383) 347‒60‒54, 8 (383) 332‒24‒37
S. M. Efremov
E.N. Meshalkin Research Institute of Blood Circulation Pathology
Russian Federation
Russian Federation
Sergey M. Efremov - Doctor of Medical Sciences, A nesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department.
15, Rechkunovskaya St., Novosibirsk, 630055,Phone/Fax: 8 (383) 347‒60‒54, 8 (383) 332‒24‒37
M. N. Аbubаkirov
E.N. Meshalkin Research Institute of Blood Circulation Pathology
Russian Federation
Russian Federation
Marat N. Abubakirov - Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department.
15, Rechkunovskaya St., Novosibirsk, 630055,Phone/Fax: 8 (383) 347‒60‒54, 8 (383) 332‒24‒37
D. N. Merekin
E.N. Meshalkin Research Institute of Blood Circulation Pathology
Russian Federation
Russian Federation
Dmitry N. Merekin - Anesthesiologist and Emergency Physician of Anesthesiology and Intensive Care Department.
15, Rechkunovskaya St., Novosibirsk, 630055,Phone/Fax: 8 (383) 347‒60‒54, 8 (383) 332‒24‒37
References
1. Bogachev-Prokofiev А.V., Sapegin А.V., Pivkin А.N. et al. Medium postponed results of preventive atrial ablation in the patients with bicuspid valve disease and atriomegaly: pilot randomized trail. Patologiya Krovoobrascheniya i Kardiokhirurgiya, 2017, no. 2, pp. 98-102. (In Russ.)
2. Lomivorotov V.V., Efremov S.M., Pokushalov E.А. et al. Atrial fibrillation after cardiac surgery: pathophysiology and methods of prevention (part 2). Vestn. Anesteziologii I Reanimatologii, 2017, vol. 14, no. 2, pp. 64-71. (In Russ.)
3. Arora P., Rajagopalam S., Ranjan R. et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin. J. Am. Soc. Nephrol., 2008, vol. 3, pp. 1266-1273.
4. Bandeali S.J., Kayani W.T., Lee V.V. et al. Outcomes of preoperative angiotensin-converting enzyme inhibitor therapy in patients undergoing isolated coronary artery bypass grafting. Am. J. Cardiol., 2012, vol. 110, pp. 919-923.
5. Benjamin E.J., Blaha M.J., Chiuve S.E. et al. Heart disease and stroke statistics-2017 update: A report from the American Heart Association. Circulation, 2017, vol. 135, pp. 146-603.
6. Bijker J.B., van Klei W.A., Vergouwe Y. et al. Intraoperative hypotension and 1-year mortality after noncardiac surgery. Anesthesiology, 2009, vol. 111, pp. 1217-1226.
7. Coriat P., Richer C., Douraki T. et al. Influence of chronic angiotensin- converting enzyme inhibition on anesthetic induction. Anesthesiology, 1994, vol. 81, pp. 299-307.
8. Deakin C.D., Dalrymple-Hay M.J., Jones P. et al. Effects of angiotensin converting enzyme inhibition on systemic vascular resistance and vasoconstrictor requirements during hypothermic cardiopulmonary bypass. Eur. J. Cardiothorac Surg., 1998, vol. 13, pp. 546-550.
9. Disque A., Neelankavil J. Con: ACE inhibitors should be stopped prior to cardiovascular surgery. J. Cardiothorac. Vasc. Anesth., 2016, vol. 30, pp. 820-822.
10. Echahidi N., Pibarot P., O’Hara G. et al. Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery. J. Am. Coll. Cardiol., 2008, vol. 51, pp. 793-801.
11. Ecoffey C., Edouard A., Pruszczynski W. et al. Effects of epidural anesthesia on catecholamines, renin activity, and vasopressin changes induced by tilt in elderly men. Anesthesiology, 1985, vol. 62, pp. 294-297.
12. Fleisher L.A., Fleischmann K.E., Auerbach A.D. et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: A report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2014, vol. 64, pp. 77-137.
13. Kearney P.M., Whelton M., Reynolds K. et al. Global burden of hypertension: Analysis of worldwide data. Lancet, 2005, vol. 365, pp. 217-223.
14. Kheterpal S., Khodaparast O., Shanks A. et al. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. J. Cardiothorac. Vasc. Anesth., 2008, vol. 22, pp. 180-186.
15. Køber L., Torp-Pedersen C., Carlsen J.E. et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med., 1995, vol. 333, pp. 1670-1676.
16. Kunz R., Friedrich C., Wolbers M. et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med., 2008, vol. 148, pp. 30-48.
17. Liu H., Yu L., Yang L. et al. Vasoplegic syndrome: An update on perioperative considerations. J. Clin. Anesth., 2017, vol. 40, pp. 63-71.
18. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J., 2013, vol. 34, pp. 2159-2219.
19. Mets B., Hennrikus E. Perioperative angiotensin axis blockade, to continue or discontinue, that is the question? Anesth. Analg., 2014, vol. 119, pp. 1223-1224.
20. Mets B. Management of hypotension associated with angiotensin-axis blockade and general anesthesia administration. J. Cardiothorac. Vasc. Anesth., 2013, vol. 27, pp. 156-167.
21. Mets B. Should norepinephrine, rather than phenylephrine, be considered the primary vasopressor in anesthetic practice?. Anesth. Analg., 2016, vol. 122, pp. 1707-1714.
22. Mets B. To stop or not? Anesth. Analg., 2015, vol. 120, pp. 1413-1419.
23. Miceli A., Capoun R., Fino C. et al. Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting. J. Am. Coll. Cardiol., 2009, vol. 54, pp. 1778-1784.
24. Monk T.G., Saini V., Weldon B.C. et al. Anesthetic management and one- year mortality after noncardiac surgery. Anesth. Analg., 2005, vol. 100, pp. 4-10.
25. Railton C.J., Wolpin J., Lam-McCulloch J. et al. Renin-angiotensin blockade is associated with increased mortality after vascular surgery. Can. J. Anaesth., 2010, vol. 57, pp. 736-744.
26. Rosenman D.J., McDonald F.S., Ebbert J.O. et al. Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period. J. Hosp. Med., 2008, vol. 3, pp. 319-325.
27. Roshanov P.S., Rochwerg B., Patel A. et al. Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: An analysis of the vascular events in noncardiac surgery patients cohort evaluation prospective cohort. Anesthesiology, 2017, vol. 126, pp. 16-27.
28. Rouleau J.L., Warnica W.J., Baillot R. et al. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery. Circulation, 2008, vol. 117, pp. 24-31.
29. Schmieder R.E., Hilgers K.F., Schlaich M.P. et al. Renin-angiotensin system and cardiovascular risk. Lancet, 2007, vol. 369, pp. 1208-1219.
30. Sousa-Uva M., Head S.J., Milojevic M. et al. 2017 EACTS guidelines on perioperative medication in adult cardiac surgery. Eur. J. Cardiothorac. Surg., 2017, vol. 53, pp. 5-33.
31. Taylor K.M., Brannan J.J., Bain W.H. et al. Role of angiotensin II in the development of peripheral vasoconstriction during cardiopulmonary bypass. Cardiovasc Res., 1979, vol. 13, pp. 269-273.
32. Tuman K.J., McCarthy R.J., O’Connor C.J. et al. Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass. Anesth. Analg., 1995, vol. 80, pp. 473-479.
33. Turan A., You J., Shiba A. et al. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery. Anesth. Analg., 2012, vol. 114, pp. 552-560.
34. Vaquero Roncero L.M., Sánchez Poveda D., Valdunciel García J.J. et al. Perioperative use of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. J. Clin. Anesth., 2017, vol. 40, pp. 91-98.
35. Venkatesan S., Myles P.R., Manning H.J. et al. Cohort study of preoperative blood pressure and risk of 30-day mortality after elective non-cardiac surgery. Br. J. Anaesth., 2017, vol. 119, pp. 65-77.
36. Vives M., Wijeysundera D., Marczin N. et al. Cardiac surgery-associated acute kidney injury. Interact. Cardiovasc. Thorac. Surg., 2014, vol. 18, pp. 637-645.
37. Walsh M., Devereaux P.J., Garg A.X. et al. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: Toward an empirical definition of hypotension. Anesthesiology, 2013, vol. 119, pp. 507-515.
38. Wright J.T., Williamson J.D. (SPRINT Research Group) et al. A randomized trial of intensive versus standard blood-pressure control. N. Engl. J. Med., 2015, vol. 373, pp. 2103-2116.
39. Yacoub R., Patel N., Lohr J.W. et al. Acute kidney injury and death associated with renin angiotensin system blockade in cardiothoracic surgery: A meta-analysis of observational studies. Am. J. Kidney Dis., 2013, vol. 62, pp. 1077-1086.
Review
For citations:
Lomivorotov V.V., Efremov S.M., Аbubаkirov M.N., Merekin D.N. IS IT WORTH TO DISCONTINUE DRUGS BLOCKING THE ACTIVITY OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN THE PERI-OPERATIVE PERIOD? Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2018;15(3):56-61. (In Russ.) https://doi.org/10.21292/2078-5658-2018-15-3-56-61
Email this article 